A new longitudinal study out of Israel was released on June 17, 2022, titled “Covid-19 vaccination BNT162b2 temporarily impairs semen concentration and total motile count among semen donors“. BNT162b2 is Pfizer’s Bio-N-Tech vaccine.
While the study says that there was “recovery” at the end of the study, they don’t mean that the levels recovered to pre-vaccination levels. They mean that the last testing was slightly better than the testing prior. See charts posted following the abstract.
The development of covid-19 vaccinations represents a notable scientific achievement. Nevertheless, concerns have been raised regarding their possible detrimental impact on male fertility
To investigate the effect of covid-19 BNT162b2 (Pfizer) vaccine on semen parameters among semen donors (SD).
37 SD from three sperm banks that provided 220 samples, were included in that retrospective longitudinal multicenter cohort study. BNT162b2 vaccination included two doses, and vaccination completion was scheduled 7 days after the second dose. The study included four phases: T0 – pre-vaccination baseline control, which encompassed 1–2 initial samples per SD; T1, T2 and T3 – short, intermediate, and long terms evaluations, respectively. Each included 1–3 semen samples per donor provided 15–45, 75-120, and over 150 days after vaccination completion, respectively. The primary endpoints were semen parameters. Three statistical analyses were conducted: 1) generalized estimated equation model; 2) first sample and 3) samples’ mean of each donor per period were compared to T0.
Repetitive measurements revealed −15.4% sperm concentration decrease on T2 (CI -25.5%–3.9%, p = 0.01) leading to total motile count 22.1% reduction (CI -35% – -6.6%, p = 0.007) compared to T0. Similarly, analysis of first semen sample only and samples’ mean per donor resulted in concentration and TMC reductions on T2 compared to T0 – median decline of 12 million/ml and 31 million motile spermatozoa, respectively (p = 0.02 and 0.002 respectively) on first sample evaluation and median decline of 9.5×106 and 27.3 million motile spermatozoa (p = 0.004 and 0.003, respectively) on samples’ mean examination. T3 evaluation demonstrated overall recovery. Semen volume and sperm motility were not impaired.
This longitudinal study focused on SD demonstrates selective temporary sperm concentration and TMC deterioration three months after vaccination followed by later recovery verified by diverse statistical analyses.
Systemic immune response after BNT162b2 vaccine is a reasonable cause for transient semen concentration and TMC decline. Long-term prognosis remains good.
This study raises serious alarm bells about the known and potential impacts on male fertility before even taking into account the impacts of continued recommendations of additional booster doses. Clearly, long term study is needed and very careful consideration must be given to risk/benefit profiles prior to participation in this procedure.